Education
About Us
Working with TipRanks
Follow Us
Veru (VERU)
NASDAQ:VERU
VERU Stock Chart & Stats
$2.34
-$0.01(-1.91%)
At close: 4:00 PM EST
$2.34
-$0.01(-1.91%)
Day’s Range― - ―
52-Week Range$2.11 - $14.20
Previous CloseN/A
Volume1.22M
Average Volume (3M)160.94K
Market Cap
$37.56M
Enterprise Value$73.55M
Total Cash (Recent Filing)$15.01M
Total Debt (Recent Filing)$3.25M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Feb 11, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding16,050,320
10 Day Avg. Volume244,731
30 Day Avg. Volume160,942
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.04
Price to Sales (P/S)0.00
P/FCF Ratio-1.85
Enterprise Value/Market Cap1.96
Enterprise Value/Revenue11.05
Enterprise Value/Gross Profit28.69
Enterprise Value/Ebitda-2.06
Forecast
1Y Price Target
$25.00Price Target Upside968.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Study SuccessThe Ph. IIb QUALITY study has achieved full enrollment of over 150 patients, with top-line data expected to provide insights into enobosarm's effectiveness.
Potential PartnershipsPositive results from the QUALITY trial could help the company secure a partnership before advancing enobosarm into a pivotal program for the treatment of obesity.
Strategic Business MovesVERU has strategically monetized its FC2 female condom business for $18M to focus solely on enobosarm's development.
Bears Say
Market CompetitionThe ease of administration for enobosarm (an oral drug) compares favorably to other competing treatment options that require intravenous administration.
Stock VolatilityA significant intra-day stock sell-off was attributed to the lack of meaningful weight loss benefits observed during the initial period of the study.
Study ChallengesThe ongoing Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for the treatment of sarcopenic obesity is on track to report topline data in January 2025.
Veru News
VERU FAQ
What was Veru’s price range in the past 12 months?
Veru lowest stock price was $2.11 and its highest was $14.20 in the past 12 months.
What is Veru’s market cap?
Veru’s market cap is $37.56M.
When is Veru’s upcoming earnings report date?
Veru’s upcoming earnings report date is Feb 11, 2026 which is in 46 days.
How were Veru’s earnings last quarter?
Veru released its earnings results on Dec 17, 2025. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of -$0.365 by $0.415.
Is Veru overvalued?
According to Wall Street analysts Veru’s price is currently Undervalued.
Does Veru pay dividends?
Veru pays a Quarterly dividend of $0.07 which represents an annual dividend yield of N/A. See more information on Veru dividends here
What is Veru’s EPS estimate?
Veru’s EPS estimate is -0.32.
How many shares outstanding does Veru have?
Veru has 16,050,320 shares outstanding.
What happened to Veru’s price movement after its last earnings report?
Veru reported an EPS of $0.05 in its last earnings report, beating expectations of -$0.365. Following the earnings report the stock price went down -8.607%.
Which hedge fund is a major shareholder of Veru?
Currently, no hedge funds are holding shares in VERU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veru Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (968.38% Upside)
$25.00 (968.38% Upside)
Blogger Sentiment
Bullish
VERU Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 653.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 8.4%
Last 30 Days ▲ 8.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.14%
12-Months-Change
Fundamentals
Return on Equity
-61.92%
Trailing 12-Months
Asset Growth
-50.94%
Trailing 12-Months
Company Description
Veru
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
VERU Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted the successful results from the Phase IIb clinical trial for enobosarm, regulatory clarity for future development, and a positive safety profile, which were overshadowed by financial losses and the need for additional capital.View all VERU earnings summariesVERU Stock 12 Month Forecast
Average Price Target
$25.00
▲(968.38% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Cue Biopharma
―
Inmune Bio
―
Celularity
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
Currently, No data available
---